Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
60
NCT04460456
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 27, 2020
Completion: Dec 31, 2022
NCT05091528
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase: Phase 1/2
Start: Feb 8, 2022
Completion: Jul 7, 2022
NCT05234606
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Start: Mar 31, 2022
Completion: Mar 31, 2022